Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lorenzo Calvetti
Observed names:
Calvetti, Lorenzo,
L. Calvetti
Institution:
Ospedale San Bortolo
Observed institutions:
University of Verona,
University of Udine,
University of Padua,
Azienda Ospedaliera Universitaria Integrata Verona,
Istituto Oncologico Veneto,
Ospedale San Bortolo,
Azienda ULSS 8 Berica
show all 7
ORCID:
0000-0002-9135-8715
Observed ORCID:
0000-0002-9135-8715
OpenAlex ID:
A5007977237
New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury
2017
·
Marika Cinausero
, Giuseppe Aprile
, et al.
·
Frontiers in Pharmacology
·
301
PDF
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors
2019
·
Alberto Pavan
, Lorenzo Calvetti
, et al.
·
The Oncologist
·
246
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study
2020
·
Alessandro Russo
, Marco Russano
, et al.
·
Advances in Therapy
·
176
Immunotherapy for colorectal cancer: where are we heading?
2017
·
Debora Basile
, Silvio Ken Garattini
, et al.
·
Expert Opinion on Biological Therapy
·
102
PDF
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?
2022
·
Laura Bonanno
, Alessandro Dal Maso
, et al.
·
British Journal of Cancer
·
83
PDF
A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study
2019
·
Fotios Loupakis
, Rossana Intini
, et al.
·
European Journal of Cancer
·
68
PDF
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer
2015
·
Fotios Loupakis
, Roberto Moretto
, et al.
·
British Journal of Cancer
·
61
PDF
SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs
2022
·
Lorenzo Belluomini
, Lorenzo Calvetti
, et al.
·
Frontiers in Oncology
·
48
PDF
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome
2021
·
Alberto Pavan
, Andrea Boscolo Bragadin
, et al.
·
Translational Lung Cancer Research
·
48
PDF
Pancreatic Cancer: Systemic Combination Therapies for a Heterogeneous Disease
2014
·
Davide Melisi
, Lorenzo Calvetti
, et al.
·
Current Pharmaceutical Design
·
37
Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience
2020
·
Laura Bonanno
, Alberto Pavan
, et al.
·
The Oncologist
·
30
CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer
2019
·
Fotios Loupakis
, Paola Biason
, et al.
·
British Journal of Cancer
·
30
PDF
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation
2021
·
Marco Russano
, Alessio Cortellini
, et al.
·
Cancer Immunology Immunotherapy
·
26
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG
2020
·
Melissa Bersanelli
, Diana Giannarelli
, et al.
·
Therapeutic Advances in Medical Oncology
·
25
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study
2023
·
Melissa Bersanelli
, Elena Verzoni
, et al.
·
EClinicalMedicine
·
24
PDF
MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database
2024
·
M.L. Reale
, F. Passiglia
, et al.
·
ESMO Open
·
18
Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis
2021
·
Matteo Fassan
, Massimo Milione
, et al.
·
European Journal of Cancer
·
18
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study
2024
·
Marco Sposito
, Lorenzo Belluomini
, et al.
·
Frontiers in Oncology
·
17
PDF
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol
2018
·
Andrea Casadei Gardini
, Luca Faloppi
, et al.
·
Tumori Journal
·
17
Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian “Real-World” SAX Study
2016
·
Carmine D'Aniello
, Maria G. Vitale
, et al.
·
Frontiers in Pharmacology
·
17
PDF
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer
2019
·
Lorenzo Fornaro
, Caterina Vivaldi
, et al.
·
British Journal of Cancer
·
16
PDF
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives
2015
·
Lorenzo Calvetti
, Sara Pilotto
, et al.
·
Expert Opinion on Biological Therapy
·
16
Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis
2024
·
Laura Bonanno
, Lorenzo Calvetti
, et al.
·
Frontiers in Immunology
·
13
PDF
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab
2020
·
Francesco Pantano
, Marco Russano
, et al.
·
Expert Opinion on Biological Therapy
·
13
Influence and mechanism of lung cavitation development on antiangiogenic therapy: is cavitation the new caveat?
2019
·
Lorenzo Calvetti
, Giuseppe Aprile
·
Translational Lung Cancer Research
·
9
PDF
Show more works
View as search
Works count:
67
Citation count:
1,521
H-index:
17
I10-index:
24
Year
Topic
Type
